The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 12 June 2026, approved a new lower dose version of the adrenaline (epinephrine) nasal spray, EURneffy, for the emergency treatment of serious allergic reactions (anaphylaxis) in children aged four years and over. This approval means younger children are eligible for a needle-free treatment option for the first time in the UK. The 1 mg dose nasal spray is indicated for […]